Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential

TSX:EDT - Post by User

Spectral Medical Inc > Baxter

<< Previous

Bullboard Posts

Next >>

Comment by oilandgasmanon Dec 08, 2023 11:09am

179 Views

Post# 35774889

RE:RE:RE:RE:RE:RE:Baxter

Valuation fantasy

Actually I have the valuation model as

$0.00013393 per share per future patient treated per year ;)

For example:

assuming 140,000 ESS patients in any given year

And 50% market penetration

so SP = ave # treated x .00013393

= 140,000 x 1/2 x .000133393

= $9.375/sh CAD

And therefore MC would be :

9.375 X 320,000,000sh

=$ 3B CAD

or $2.2 B USD

And then once USA PMX rights are sold off :

That leaves spectral shareholders with

1. worldwide EAA rights and
2. 30% interest in future US iDialco ( obviously back burnered until (a) Infomed can figure out how to break into the US market and compete against Baxter, Fresenius, etc., and (B) the DaVitas of this world can figure out the remaining issues on Home dialysis ( eg legal, insurance, etc)
3. royalty on use of SAMI and DIMI for HP in Europe and ROW

For the enriched students out there, that is a little over 2 times revenue.... conservative by PS ratio standards.